Table 1.
Demographic and management characteristics of COVID-19 case series including abdominal organ transplant recipients.
| References | Demographic characteristics | COVID-19 Management | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Country | Patients | Age (mean ± SD) | Males | Transplanted organs | Time from transplantation (median, IQR) | Immunosuppression tapered/stopped | LPV/r | HCQ | Tocilizumab | |
| Fernández-Ruiz et al. (15) | Spain | 18 | 71.0 ± 12.8 | 14/18 (77.8) | Kidney (8/18), Liver (6/18), Heart (4/18) | 9.3 (6.3–16.5) | 15/18 (83.3) | 9/18 (50.0) | 14/18 (77.8) | 1/18 (5.6) |
| Zhu et al. (16) | China | 10 | 45.0 ± 14.0 | 8/10 (80.0) | Kidney | N/A | 9/10 (90.0) | N/A | N/A | N/A |
| Columbia University (17) |
USA | 15 | 50.6 ± 21.4 | 10/15 (66.7) | Kidney | 4.1 (3.2–9.8) | 14/15 (93.4) | N/A | 13/15 (86.7) | 1/15 (6.7) |
| Pereira et al. (18) | USA | 90 | 57 (46-68)a | 53 (58.9) | Kidney (46/90), Lung (17/90), Liver (13/90), Heart (9/90), Heart-Kidney (3/90), Liver-Kidney (1/90), Kidney- Pancreas (1/90) |
6.64 (2.87–10.61) | 42/48 (87.5)b, 3/43 (7.0)c, 10/56 (17.9)d |
N/A | 62/90 (68.9) | 14/90 (15.6) |
| Akalin et al. (19) | USA | 36 | 57.2 ± 11.2 | 26/36 (72.2) | Kidney | N/A | 24/28 (85.8)b, 6/28 (21.4)c |
N/A | 24/28 (85.7) | 2/36 (5.5) |
| Donato et al. (20) | Italy | 8 | 63.0 + 9.4 | 6/8 (75.0) | Liver | 9.7 (3.6–17.1) | N/A | N/A | N/A | N/A |
a
Given as median (range);
b
Discontinuation or tapering of antimetabolites;
c
Discontinuation or tapering of corticosteroids;
d
Discontinuation or tapering of calcineurin inhibitors.
SD, standard deviation; IQR, interquartile range; LPV/r, lopinavir/ritonavir; HCQ, hydroxychloroquine; N/A, not available.
Numbers in parentheses denote percentages.